Stuart and Molly Sloan Precision Oncology Institute Research Funding Opportunities
Since 2024, the Sloan Precision Oncology Institute has supported innovative precision oncology research through our research funding awards. To date, ten projects have been funded through our Ignition and Technology Dissemination Awards.
Upcoming Funding Opportunities
In mid-May, the Stuart and Molly Sloan Precision Oncology Institute will once again be requesting innovative, forward-thinking proposals centered on Investigators’ interpretation of Precision Oncology that address a research hypothesis (IGNITION Award) or that focus on disseminating novel technologies to the research community (TECHNOLOGY DISSEMINATION Award). It is anticipated that one Technology Dissemination Award and three Ignition Awards will be supported.
Prior to preparing full applications, Investigators will submit a 1-page Letter of Intent providing a brief description of the research to be conducted and its relevance to Precision Oncology. The competition will open, and full LOI and application instructions will be shared, on May 15, 2026. LOIs will be due by June 15; successful LOI applicants will be informed on June 30 and asked to submit a full proposal by August 10, 2026.
Please check back here to learn more about the science we’re funding or to participate in our upcoming funding opportunities and join us in our mission to improve cancer outcomes through developing personalized prevention, early detection, and treatment strategies.
Sloan Precision Oncology Institute 2025 Ignition and Technology Dissemination Awardees
In early 2025, the Stuart and Molly Sloan Precision Oncology Institute invited investigators at Fred Hutch Cancer Center, University of Washington and Seattle Children’s Research Institute to submit innovative, forward-thinking proposals centered on Precision Oncology that address a research hypothesis (Ignition Award) or that focus on disseminating novel technologies to the research community (Technology Dissemination Award). A total of 34 outstanding applications were submitted.
After a thorough review process, three Ignition and two Technology Dissemination projects were selected for funding. Ignition Awards will provide $75,000 in funding for one year, and Technology Dissemination Awards will provide funding of $250,000 over two years. This year, funding will support projects led by Investigators at Fred Hutch and University of Washington and represent a diverse range of research to advance precision oncology.
2025 Ignition Awards
Igniting targeted treatment strategies

GRIP Imaging for Imaging T Cell Immunotherapy Responses
Dr. Delphine Chen, professor of Radiology at UW Medicine, Wil B. Nelp M.D. Endowed Professorship in Nuclear Medicine, and director of Molecular Imaging and Therapy at Fred Hutch, was awarded an Ignition Award for her proposal titled “GRIP imaging for imaging T cell immunotherapy responses.” Delphine’s proposal aims to elucidate the kinetics of T-cell activation in response to immunotherapy by utilizing novel imaging modalities. This approach will enable enhanced clinical decision-making support for determining the duration of therapy and the risk of toxicity to internal organs, as well as assessing the overall efficacy of the immunotherapy regimen.

Understanding and Exploiting MYC-Network Interactions to Thwart MYC Addicted Cancers
Dr. Robert (Bob) Eisenman, professor in Fred Hutch’s Basic Sciences Division, was awarded an Ignition Award for his proposal titled “Understanding and exploiting MYC-network interactions to thwart MYC-addicted cancers.” Bob’s proposal focuses on an innovative approach to interfering with the MYC family of oncogenic transcription factors by targeting MondoA, a transcription factor that regulates metabolic and stress-response related gene expression. This work will focus on pancreatic adenocarcinoma by determining the molecular mechanisms of how inhibition of MondoA can arrest tumor cell growth in this disease state. This work has the potential for targeting tumor vulnerabilities across the spectrum of MYC-dependent cancers.

Identification of Aberrant Splicing-Derived Targets for Cancer Immunotherapies
Dr. Stanley Lee, an associate professor in Fred Hutch’s Translational Science and Therapeutics Division, was awarded an Ignition Award for his work focused on “Identification of Aberrant Splicing-Derived Targets for Cancer Immunotherapies.” Myeloid malignancies can comprise clonal mutations that drive widespread splicing dysregulation, cumulating in the production of tumor-specific peptides present on HLA molecules. This provides an opportunity for the identification of mutation specific targets, and Stanley intends to utilize ARTEMIS (a high-yield proteogenomic-platform), in conjunction with RNA-seq and proteomics data, to improve prediction capabilities for identifying novel immunotherapy strategies.
2025 Technology Dissemination Awards
Expanding access to precision oncology tools for broadening and improving research

Scorcher: Democratizing AI/ML Workflows for Precision Oncology
A Technology Dissemination Award went to Dr. Jeff Leek, vice president and chief data officer, J. Orin Edson Foundational Endowed Chair and professor in the Biostatistics Program at Fred Hutch, and co-investigator Dr. Stephen Salerno, a postdoctoral researcher in the Public Health Sciences Division, for their proposal centered on developing a shared approach to artificial intelligence (AI) and machine learning (ML) across the Fred Hutch/University of Washington/Seattle Children's Cancer Consortium. Jeff and Stephen have previously developed an AI/ML tool, termed Scorcher, that enables easy-to-use access to model development. Throughout the course of this award, they intend to pilot Scorcher with physician-investigator champions who have developed the necessary datasets ready for AI/ML input. These pilot collaborations will enable the identification of user needs, pain points and priorities, that can be adapted to expand access to Scorcher across the Cancer Consortium, alongside educational workshops and training.

Dissemination of a Single-Molecule-Sensitive Digital Flow Cytometer
Dr. Daniel Chiu, professor of Chemistry and Bioengineering at the University of Washington, was awarded a Technology Dissemination Award for his work involving the “Dissemination of a single-molecule-sensitive digital flow cytometer.” Extra cellular vesicles (EVs) secreted by cells provide an option for non-invasive, liquid biopsy in the early detection of cancer. Daniel and team have developed a highly sensitive methodology for EV capture and phenotyping and will utilize the support from this award to make the technology available to the Cancer Consortium as a shared resource in the Fred Hutch and UW Flow Cytometry cores. Further, dissemination of this novel technology will allow for continuous refinement of the technology, allowing for broad application across the research community.
Extending Congratulations and Thanks for Advancing Precision Oncology Research With Us Again in 2025
Congratulations to Drs. Delphine Chen, Bob Eisenman, Stanley Lee, Jeff Leek, Stephen Salerno and Daniel Chiu! We are excited to see the contributions each Investigator will make to advancing precision oncology research here at Fred Hutch and across the Cancer Consortium.
The Sloan Precision Oncology Institute team is very grateful to the faculty and community advisory board members that participated in the rigorous review process. Thank you also to the many members of our research community who submitted proposals for Ignition and Technology Dissemination Awards. The quality and innovation made funding decisions very difficult. Once again, the excellence and innovation of the research proposals from our applicants provides motivation to continue this RFA funding mechanism in the future.
2024 Ignition and Technology Dissemination Awards
In 2024, three Ignition and two Technology Dissemination projects were selected for funding. Information about our earlier awards are maintained here: Past Research Funding Awards.